In France, the forecasted hospital average length of stay for malignant neoplasm of the prostate is set to decrease from 4.3 days in 2024 to 3.4 days by 2028. This marks a steady downward trend, reflecting a year-on-year decline of approximately 4.7% from 2025 to 2028. The compound annual growth rate (CAGR) over this forecast period is about -5.6%, indicating a consistent effort in reducing hospital stays, likely due to advances in medical technology and practice efficiency.
Future trends to watch for include the impact of emerging treatment protocols and technologies, such as precision medicine and minimally invasive procedures, on reducing recovery times and hospital stays even further. Additionally, the integration of telemedicine in post-treatment care will likely continue to influence these metrics.
